Serotonin Estrogen Axis

Overview

The serotonin-estrogen axis describes the bidirectional relationship between estrogen signaling and serotonin (5-HT) neurotransmission — a neuroendocrine interface that is profoundly modulated by the gut microbiome. Estrogen regulates serotonin synthesis (via tryptophan hydroxylase expression), serotonin receptor density (5-HT2A), and serotonin reuptake transporter (SERT) expression. Conversely, serotonin modulates hypothalamic GnRH pulsatility, affecting estrogen production. The gut microbiome sits at the center of both systems: it controls estrogen recirculation (estrobolome) and produces ~95% of the body's serotonin via enterochromaffin cell stimulation.

The Microbiome Connection

Three microbiome pathways converge on this axis:

  1. Estrobolome → estrogen levels: Gut bacterial beta glucuronidase deconjugates estrogens, increasing circulating free estrogen. Dysbiosis alters the estrobolome, disrupting estrogen homeostasis [1].
  1. Tryptophan metabolism → serotonin: The microbiome modulates tryptophan availability for serotonin synthesis. Dysbiosis-driven inflammation shunts tryptophan into the kynurenine pathway (via IDO/TDO), reducing serotonin precursor availability.
  1. SCFA → enterochromaffin cells → 5-HT release: Short-chain fatty acids (particularly butyrate) stimulate enterochromaffin cells to release serotonin. SCFA depletion from dysbiosis reduces peripheral serotonin production.

Clinical Relevance

  • PMDD: Abnormal serotonergic sensitivity to estrogen/progesterone fluctuations across the menstrual cycle. The interaction between allopregnanolone (GABA-A modulator), estrogen, and serotonin defines PMDD neurobiology [2] [3] [4].
  • Postpartum depression: Precipitous estrogen drop at delivery disrupts the serotonin-estrogen equilibrium. Inflammatory biomarkers (IL-6, TNF-alpha) compound the disruption [5].
  • Menopausal depression: Estrogen decline reduces serotonergic tone → increased depression risk.
  • Endometriosis: Estrogen excess (via dysbiotic estrobolome) drives lesion growth while serotonergic disruption drives associated pain and mood symptoms.

Cross-References

References (5)

  1. Kanakaraju Kaliannan, Ruairi C. Robertson, Kiera Murphy et al. (2018). Kaliannan et al. 2018 — Estrogen-Mediated Gut Microbiome Alterations Influence Sexual Dimorphism in Metabolic Syndrome in Mice. Microbiome. doi:10.1186/s40168-018-0587-0
  2. Cheng et al. (2025). Cheng 2025 — Neuroinflammation in PMS and PMDD (Review). Frontiers in Endocrinology. doi:10.3389/fendo.2025.1561848
  3. Khalida Itriyeva (2022). Itriyeva 2022 — PMS and PMDD in Adolescents (Review). Current Problems in Pediatric and Adolescent Health Care. doi:10.1016/j.cppeds.2022.101187
  4. Adile Nexha, Luisa Caropreso, Taiane de Azevedo Cardoso et al. (2024). Nexha 2024 — Biological Rhythms in PMS/PMDD (Systematic Review). BMC Women's Health. doi:10.1186/s12905-024-03395-3
  5. Anabela Silva-Fernandes, Ana Conde, Margarida Marques et al. (2024). Silva-Fernandes 2024 — Inflammatory Biomarkers and Perinatal Depression: A Systematic Review. PLOS ONE. doi:10.1371/journal.pone.0280612

Related Articles